Upcoming Webinars Archived Webinars Training Vitals Host A Webinar About Get Updates Contact

Eye Test Could Lead To Early Detection Of Parkinson’s Disease

XTALKS VITALS NEWS

In addition to helping patients receive an early diagnosis, the technique could be used to monitor patient response to Parkinson’s treatment.

Tweetables from this article:

Tweet: Parkinson’s disease is the second most common neurodegenerative disease worldwide. http://ctt.ec/Bk0s9+ "Parkinson’s disease is the second most common neurodegenerative disease worldwide."

Share this!

August 31, 2016 | by Sarah Massey, M.Sc.

An inexpensive, non-invasive eye test could help physicians diagnose Parkinson’s disease, before the onset of debilitating symptoms, such as muscle stiffness and tremors. Using rat models, researchers at the UCL Institute of Ophthalmology have developed a new method of monitoring retinal changes consistent with the early stages of Parkinson’s.

The method uses ophthalmic instruments to perform optical coherence tomography (OCT) – a technology which is already in use by optometrists and other eye care professionals. The method developed by the researchers was published in the journal, Acta Neuropathologica Communications. In addition to helping patients receive an early diagnosis, the technique could be used to monitor patient response to Parkinson’s treatment. The same technique has been tested on people with glaucoma, and clinical trials involving Alzheimer’s patients are set to start soon.

“This is potentially a revolutionary breakthrough in the early diagnosis and treatment of one of the world's most debilitating diseases,” said study leader Professor Francesca Cordeiro, UCL Professor of Glaucoma & Retinal Neurodegeneration Studies. “These tests mean we might be able to intervene much earlier and more effectively treat people with this devastating condition.”



Parkinson’s disease is the second most common neurodegenerative disease worldwide, with an incidence rate of approximately one in every 500 people. Symptoms of Parkinson’s disease – including tremors, muscle stiffness and slowness of movement – usually do not manifest themselves until nearly three quarters of the brain’s dopamine-secreting cells have been irreversibly damaged.

After visualizing the retinal changes in the rat model of Parkinson’s disease, Cordeiro and her colleagues treated the subjects with a neuroprotectant anti-diabetic drug, Rosiglitazone. The drug was found to reduce retinal cell death, indicating that it could be a potentially promising treatment for Parkinson’s disease.

“These discoveries have the potential to limit and perhaps eliminate the suffering of thousands of patients if we are able to diagnose early and to treat with this new formulation,” said Dr. Eduardo Normando, Consultant Ophthalmologist at Western Eye Hospital and UCL, and primary author on the publication. “The evidence we have strongly suggests that we might be able to intervene much earlier and more effectively in treating people with this devastating condition, using this non-invasive and affordable imaging technique.”


Keywords: Parkinson's Disease, Early Detection, Alzheimer's


| NEXT ARTICLE | MORE NEWS | BLOGS | VIDEOS | POLLS & QUIZZES | WEBINARS |

Share this with your colleagues!

MORE NEWS
German Merck Launches Spinoff Immuno-Oncology Company

June 22, 2017 - Merck KGaA has announced the launch of iOnctura SA, a new immuno-oncology company built around two assets from the Healthcare R&D portfolio of the pharmaceutical company.

Featured In: Biotech News


Ikea Promotes Food Products by Offering Fill-in-the-Blanks Recipe Sheets

June 21, 2017 - In an effort to promote the company’s food business, Ikea recently launched a set of recipes printed on parchment paper that encourage consumers to “fill-in-the-blanks” with ingredients, fold the paper and cook the bag in the oven.

Featured In: Food News


Nanomaterial Promotes Bone Growth after Spinal Fusion Surgery

June 21, 2017 - Researchers at Northwestern University have developed a bioactive nanomaterial capable of effectively stimulating bone regeneration after spinal fusion surgery.

Featured In: Life Science News


LEAVE A COMMENT
 
  
THE XTALKS VITALS INDUSTRY BLOG

Top 5 Most Impactful Tweets in Drug Development During the Last Week

REGISTER FOR THESE WEBINARS

Serialized? Yes. But are Products Still Being Diverted?


Quantitative Protein Profiling in FFPE to Characterize Toxicities Associated with Immune Checkpoint Inhibitors


Are You Choosing the Right Model? A Guide to Selecting Your Next Immuno-Oncology Model


Imaging-based Subtypes of Pancreatic Cancer


Copyright © 2016-2017 Honeycomb Worldwide Inc.